Posted by Michael Wonder on 04 Dec 2018
Enstilar is now covered by the Alberta Drug Benefit List for adults with psoriasis vulgaris
3 December 2018 - Leo Pharma Canada has announced that as of 1 December 2018, Enstilar has been added as a Regular Benefit through the Alberta Drug Benefit List.
Enstilar (calcipotriol and betamethasone dipropionate) is a spray foam for once-daily topical treatment of psoriasis vulgaris in adults.
Enstilar already received approval for the Régie de l'Assurance Maladie du Québec on 1 June 2017, Saskatchewan Drug Plan on 1 January 2018, Non-Insured Health Benefits on 15 October 2018, New Brunswick Drug Plan on 8 November 2018 and Ontario Drug Benefit on 31 October 2018.
